# US 2026/0085314 A1 · Conjugated oligonucleotide compounds, methods of making and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085314 A1
- Document ID: US20260085314A1
- Status: Published application
- Kind: A1
- Application number: 19/211,026
- Filed: 2025-05-16
- Published: 2026-03-26
- Earliest claimed: 2021-01-30
- Assignees: E-Therapeutics PLC
- Applicants: E-Therapeutics PLC
- Inventors: Ahmad Ali MORTAZAVI; Viviana MANNELLA; Muthusamy JAYARAMAN
- Web page: https://patentgrep.com/patent/US20260085314A1

## CPC

- C07H 15/08: Polyoxyalkylene derivatives
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- C07D 207/404: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07H 15/04: attached to an oxygen atom of the saccharide radical
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 21/02: with ribosyl as saccharide radical
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/30: chemically synthesised
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compounds for the treatment of various diseases and conditions.

## Claims

### Claim 1

A method of preparing a compound of Formula (I):
the method comprising conjugating a compound of Formula (XII):
with a compound of Formula (XIII):
wherein:
R1 at each occurrence is independently selected from the group consisting of hydrogen, methyl, and ethyl;
R2 is fluoro or hydroxy;
X1 and X2 at each occurrence are independently selected from the group consisting of methylene, oxygen, and sulfur;
m is an integer of from 1 to 6;
n is an integer of from 1 to 10;
q, r, s, t, v are independently integers from 0 to 4, wherein:
(i) q and r cannot both be 0 at the same time; and
(ii) s, t, and v cannot all be 0 at the same time; and
Z is an oligonucleotide moiety; and
deprotecting the ligand moiety and/or annealing a second strand to the oligonucleotide moiety.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound of Formula (XII) is prepared by conjugating a compound of Formula (XIV):
with a compound of Formula (XV):
wherein:
R1 at each occurrence is independently selected from the group consisting of hydrogen, methyl, and ethyl;
R2 is fluoro or hydroxy;
X1 and X2 at each occurrence are independently selected from the group consisting of methylene, oxygen, and sulfur;
q, r, s, t, v are independently integers from 0 to 4, wherein:
(i) q and r cannot both be 0 at the same time; and
(ii) s, t, and v cannot all be 0 at the same time; and
Z is an oligonucleotide moiety.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
the compound of Formula (XII) is a compound of Formula (XIIa):
the compound of Formula (XIII) is a compound of Formula (XIIIa):
the oligonucleotide comprises an RNA duplex comprising a first strand and a second strand;
the first strand is at least partially complementary to an RNA sequence of a target gene, and the second strand is at least partially complementary to the first strand; and
the RNA duplex is attached to an adjacent phosphate at the 5′ end of the second strand.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
the compound of Formula (XII) is a compound of Formula (XIIb):
the compound of Formula (XIII) is a compound of Formula (XIIIa):
the oligonucleotide comprises an RNA duplex comprising a first strand and a second strand;
the first strand is at least partially complementary to an RNA sequence of a target gene, and the second strand is at least partially complementary to the first strand; and
the RNA duplex is attached to an adjacent phosphate at the 5′ end of the second strand.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
the compound of Formula (XII) is a compound of Formula (XIIc):
the compound of Formula (XIII) is a compound of Formula (XIIIa):
the oligonucleotide comprises an RNA duplex comprising a first strand and a second strand;
the first strand is at least partially complementary to an RNA sequence of a target gene, and the second strand is at least partially complementary to the first strand; and
the RNA duplex is attached to an adjacent phosphate at the 3′ end of the second strand.

### Claim 6 (depends on 1)

The method of claim 1, wherein:
the compound of Formula (XII) is a compound of Formula (XIId):
the compound of Formula (XIII) is a compound of Formula (XIIIa):
the oligonucleotide comprises an RNA duplex comprising a first strand and a second strand;
the first strand is at least partially complementary to an RNA sequence of a target gene, and the second strand is at least partially complementary to the first strand; and
the RNA duplex is attached to an adjacent phosphate at the 3′ end of the second strand.

### Claim 7 (depends on 3)

The method of claim 3, wherein the compound of Formula (XIIIa) is a compound of Formula (XIIIb):

### Claim 8 (depends on 2)

The method of claim 2 wherein:
the compound of Formula (XIV) is either a compound of Formula (XIVa):
or a compound of Formula (XIVa):
the compound of Formula (XV) is either a compound of Formula (XVa):
or Formula (XIVb):
the oligonucleotide comprises an RNA duplex comprising a first strand and a second strand;
the first strand is at least partially complementary to an RNA sequence of a target gene, and the second strand is at least partially complementary to the first strand; and
(i) the RNA duplex is attached to an adjacent phosphate in Formula (XVa) at the 5′ end of the second strand, or (ii) the RNA duplex is attached to an adjacent phosphate in Formula (XVb) at the 3′ end of the second strand.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient, wherein the compound of Formula (I) is formed using the method of claim 1.

### Claim 10 (depends on 1)

A method of treatment comprising administering the compound of Formula (I) to an individual, wherein the compound of Formula (I) is formed using the method of claim 1.

### Claim 11 (depends on 1)

The method of claim 1, wherein R1 is hydrogen.

### Claim 12 (depends on 1)

The method of claim 1, wherein X1 and X2 are both methylene.

### Claim 13 (depends on 1)

The method of claim 1, wherein m is 3 and n is 6.

### Claim 14 (depends on 1)

The method of claim 1, wherein q is 1 and r is 3.

### Claim 15 (depends on 1)

The method of claim 1, wherein s, t, and v are each 1.

### Claim 16 (depends on 1)

The method of claim 1, wherein the conjugating is carried out in an aprotic polar solvent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the aprotic polar solvent is dimethylformamide (DMF) or dimethyl sulfoxide (DMSO).

### Claim 18 (depends on 1)

The method of claim 1, wherein the conjugating is carried out at a temperature between 20° C. and 60° C.

### Claim 19 (depends on 1)

The method of claim 1, further comprising purifying the compound of Formula (I) by high-performance liquid chromatography (HPLC).
